Cubosomal nanoformulation increase in vitro dissolution and anticancer activity of Fisetin in A549 lung cancer cells

References

• Zhou C, Huang Y, Nie S et al. Biological effects and mechanisms of fisetin in cancer: a promising anti-cancer agent. Eur. J. Med. Res. 28(1), 297 (2023).
   PubMed Web of Science ®Google Scholar
• Kumar RM, Kumar H, Bhatt T et al. Fisetin in cancer: attributes, developmental aspects, and nanotherapeutics. Pharmaceuticals 16(2), 196 (2023).
   Web of Science ®Google Scholar
• Qaed E, Al-Hamyari B, Al-Maamari A et al. Fisetin's promising antitumor effects: uncovering mechanisms and targeting for future therapies. Glob Med. Genet. 10(3), 205–220 (2023).
   PubMedGoogle Scholar
• Kashyap D, Garg VK, Tuli HS et al. Fisetin and quercetin: promising flavonoids with chemopreventive potential. Biomolecules 9(5), 174 (2019).
   PubMed Web of Science ®Google Scholar
• Afroze N, Pramodh S, Shafarin J et al. Fisetin deters cell proliferation, induces apoptosis, alleviates oxidative stress and inflammation in human cancer cells, HeLa. Int. J. Mol. Sci. 23(3), 1707 (2022).
   PubMed Web of Science ®Google Scholar
• Eguchi H, Kimura R, Matsunaga H et al. Increase in anticancer drug-induced toxicity by fisetin in lung adenocarcinoma A549 spheroid cells mediated by the reduction of claudin-2 expression. Int. J. Mol. Sci. 23(14), 7536 (2022).
   PubMed Web of Science ®Google Scholar
• Jeong HM, Kang HN, Lee YR et al. Improved low water solubility of fisetin by enzymatic encapsulation reaction using cycloamylose produced by cyclodextrin glucanotransferase. Process Biochem. 130, 138–146 (2023).
   Web of Science ®Google Scholar
• Wang Y, Wu X, Ren W et al. Protective effects of fisetin in an Aβ1-42-induced rat model of Alzheimer's disease. Folia Neuropathol. 61(1), 196–208 (2023).
   PubMedGoogle Scholar
• Huard CA, Gao X, Dey Hazra ME et al. Effects of fisetin treatment on cellular senescence of various tissues and organs of old sheep. Antioxidants 12(8), 1646 (2023).
   Web of Science ®Google Scholar
• Mitra S, Ghosh N, Paul P et al. Orally administered fisetin reduces the symptoms of acute allergic asthma in a preclinical mouse model. Biomed. Res. Ther. 9(3), 4953–4970 (2022).
   Web of Science ®Google Scholar
• Talaat SM, Elnaggar YSR, Gowayed MA et al. Novel PEGylated cholephytosomes for targeting fisetin to breast cancer: in vitro appraisal and in vivo antitumoral studies. Drug Deliv. Transl. Res. 14(2), 433–454 (2023).
   PubMed Web of Science ®Google Scholar
• Awadeen RH, Boughdady MF, Zaghloul RA et al. Formulation of lipid polymer hybrid nanoparticles of the phytochemical Fisetin and its in vivo assessment against severe acute pancreatitis. Sci. Rep. 13(1), 19110 (2023).
   PubMed Web of Science ®Google Scholar
• Szymczak J, Cielecka-Piontek J. Fisetin-in search of better bioavailability-from macro to nano modifications: a review. Int. J. Mol. Sci. 24(18), 14158 (2023).
   PubMed Web of Science ®Google Scholar
• Ragelle H, Heloise R, Crauste-Manciet S, Seuign J et al. Nanoemulsion formulation of fisetin improves bioavailability and antitumour activity in mice. Int. J. Pharm. 427(2), 452 (2012).
   PubMed Web of Science ®Google Scholar
• Aboushanab AR, El-Moslemany RM, El-Kamel AH et al. Targeted fisetin-encapsulated β-cyclodextrin nanosponges for breast cancer. Pharmaceutics 15(5), 1480 (2023).
   PubMed Web of Science ®Google Scholar
• Seguin J, Brullé L, Boyer R et al. Liposomal encapsulation of the natural flavonoid fisetin improves bioavailability and antitumor efficacy. Int. J. Pharm. 444(1–2), 146–154 (2013).
   PubMed Web of Science ®Google Scholar
• Mignet N, Seguin J, Ramos Romano M et al. Development of a liposomal formulation of the natural flavonoid fisetin. Int. J. Pharm. 423(1), 69–76 (2012).
   PubMed Web of Science ®Google Scholar
• Ghosh P, Singha Roy A, Chaudhury S et al. Preparation of albumin based nanoparticles for delivery of fisetin and evaluation of its cytotoxic activity. Int. J. Biol. Macromol. 86, 408–417 (2016).
   PubMed Web of Science ®Google Scholar
• Moolakkadath T, Aqil M, Ahad A et al. Development of transethosomes formulation for dermal fisetin delivery: Box – Behnken design, optimization, in vitro skin penetration, vesicles – skin interaction and dermatokinetic studies. Artif. Cell Nanomed. Biotechnol. 46(Suppl. 2), 755–765 (2018).
   PubMedGoogle Scholar
• Xiao X, Zou J, Fang Y et al. Fisetin and polymeric micelles encapsulating fisetin exhibit potent cytotoxic effects towards ovarian cancer cells. BMC Complement. Altern. Med. 18(1), 1–2 (2018).
   PubMedGoogle Scholar
• Moolakkadath T, Aqil M, Ahad A et al. Fisetin loaded binary ethosomes for management of skin cancer by dermal application on UV exposed mice. Int. J. Pharm. 560, 78–91 (2019).
   PubMedGoogle Scholar
• Moolakkadath T, Aqil M, Ahad A et al. Preparation and optimization of fisetin loaded glycerol based soft nanovesicles by Box-Behnken design. Int. J. Pharm. 578, 119125 (2020).
   PubMed Web of Science ®Google Scholar
• Kumar R, Khursheed R, Kumar R et al. Self-nanoemulsifying drug delivery system of fisetin: formulation, optimization, characterization and cytotoxicity assessment. J. Drug Deliv. Sci. Technol. 54, 101252 (2019).
   Web of Science ®Google Scholar
• Kumar R, Khurana N, Sharma N et al. Formulation of liquisolid powder of Fisetin. Eur. J. Mol. Clin. Med. 7(7), 4391–4397 (2020).
   Google Scholar
• Skiba M, Gasmi H, Milon N et al. Water solubility and dissolution enhancement of fisetin by spherical amorphous solid dispersion in polymer of cyclodextrin. J. Adv. Biotechnol. Bioeng 8, 1106 (2021).
   Google Scholar
• Liu WY, Lin CC, Hsieh YS. Nanoformulation development to improve the biopharmaceutical properties of fisetin using design of experiment approach. Molecules 26(10), 3031 (2021).
   PubMed Web of Science ®Google Scholar
• Lorthongpanich N, Mahalapbutr P, Rungrotmongkol T et al. Fisetin glycosides synthesized by cyclodextrin glycosyltransferase from Paenibacillus sp. RB01: characterization, molecular docking, and antioxidant activity. PeerJ 10, e13467 (2022).
   PubMed Web of Science ®Google Scholar
• Lorenzo GD, Scafuri L, Costabile F et al. Fisetin as an adjuvant treatment in prostate cancer patients receiving androgen-deprivation therapy. Futur. Sci. OA 8(3), FSO784 (2022).
   PubMed Web of Science ®Google Scholar
• Cytryniak A, Nazaruk E, Bilewicz R et al. Lipidic cubic-phase nanoparticles (Cubosomes) loaded with doxorubicin and labeled with177 lu as a potential tool for combined chemo and internal radiotherapy for cancers. Nanomaterials 10(11), 2272 (2020).
   Web of Science ®Google Scholar
• Nazaruk E, Majkowska-Pilip A, Bilewicz R. Lipidic cubic-phase nanoparticles-cubosomes for efficient drug delivery to cancer cells. Chempluschem 82(4), 570–575 (2017).
   PubMed Web of Science ®Google Scholar
• Flak DK, Adamski V, Nowaczyk G et al. At101-loaded cubosomes as an alternative for improved glioblastoma therapy. Int. J. Nanomed. 15, 7415–7431 (2020).
   PubMed Web of Science ®Google Scholar
• Sivadasan D, Sultan MH, Alqahtani SS et al. Cubosomes in drug delivery-A comprehensive review on its structural components, preparation techniques and therapeutic applications. Biomedicines 11(4), 1114 (2023).
   PubMed Web of Science ®Google Scholar
• Kedar T, Jalalpure S, Kurangi B et al. Development and validation of stability-indicating RP-HPLC method for the estimation of fisetin in novel cubosomal nanoformulation: application to the marketed formulation and selected plant extracts. Curr. Pharm. Anal. 18(10), 983–992 (2022).
   Web of Science ®Google Scholar
• Alshawwa SZ, El-Masry TA, Nasr M et al. Celecoxib-loaded cubosomal nanoparticles as a therapeutic approach for Staphylococcus aureusin vivo infection. Microorganisms 11(9), 2247 (2023).
   PubMed Web of Science ®Google Scholar
• Sultan AA, Nashar NF, Ashmawy SM et al. Cubosomes for enhancing intestinal absorption of fexofenadine hydrochloride: in situ and in vivo investigation. Int. J. Nanomedicine 17, 3543–3560 (2022).
   PubMed Web of Science ®Google Scholar
• Karami Z, Hamidi M. Cubosomes: remarkable drug delivery potential. Drug Discov. Today 21(5), 789–801 (2016).
   PubMed Web of Science ®Google Scholar
• Kurangi B, Jalalpure S, Jagwani S. Formulation and evaluation of resveratrol loaded cubosomal nanoformulation for topical delivery. Curr. Drug Deliv. 18(5), 607–619 (2021).
   PubMed Web of Science ®Google Scholar
• Shi X, Peng T, Huang Y et al. Comparative studies on glycerol monooleate- and phytantriol-based cubosomes containing oridonin in vitro and in vivo. Pharm. Dev. Technol. 22(3), 322–329 (2017).
   PubMed Web of Science ®Google Scholar
• Bei D, Marszalek J, Youan BB. Formulation of dacarbazine-loaded cubosomes-part I: influence of formulation variables. AAPS PharmSciTech. 10, 1032–1039 (2009).
   PubMed Web of Science ®Google Scholar
• Bei D, Marszalek J, Youan BB. Formulation of dacarbazine-loaded cubosomes-part II: influence of process parameters. AAPS PharmSciTech. 10, 1040–1047 (2009).
   PubMed Web of Science ®Google Scholar
• Bei D, Zhang T, Murowchick JB et al. Formulation of dacarbazine-loaded cubosomes. Part III. physicochemical characterization. AAPS PharmSciTech. 11, 1243–1249 (2010).
   PubMed Web of Science ®Google Scholar
• Chishti N, Jagwani S, Dhamecha D et al. Preparation, optimization, and in vivo evaluation of nanoparticle-based formulation for pulmonary delivery of anticancer drug. Medicina 55(6), 294 (2019).
   PubMedGoogle Scholar
• Ahirrao M, Shrotriya S. In vitro and in vivo evaluation of cubosomal in situ nasal gel containing resveratrol for brain targeting. Drug Dev. Ind. Pharm. 43(10), 1686–1693 (2017).
   PubMed Web of Science ®Google Scholar
• Chettupalli AK, Ananthula M, Amarachinta PR et al. Design, formulation, in-vitro and ex-vivo evaluation of atazanavir loaded cubosomal gel. Biointerface Res. Appl. Chem. 11, 12037–12054 (2021).
   Web of Science ®Google Scholar
• Hakeem EA, El-Mahrouk GM, Abdelbary G et al. Freeze-dried clopidogrel loaded lyotropic liquid crystal: Box-Behnken optimization, in-vitro and in-vivo evaluation. Curr. Drug Deliv. 17(3), 207–217 (2020).
   PubMed Web of Science ®Google Scholar
• Kumar KN, Mallik S, Sarkar K. Role of freeze-drying in the presence of mannitol on the echogenicity of echogenic liposomes. J. Acoust Soc. Am. 142(6), 3670–3676 (2017).
   PubMed Web of Science ®Google Scholar
• Nasr M, Younes H, Abdel-Rashid RS. Formulation and evaluation of cubosomes containing colchicine for transdermal delivery. Drug Deliv. Transl. Res. 10, 1302–1313 (2020).
   PubMed Web of Science ®Google Scholar
• Hundekar YR, Saboji JK, Patil SM et al. Preparation and evaluation of Diclofenac sodium Cubosomes for percutaneous administration. World Journal of Pharmacy and Pharmaceut. Sci. 3(1), 523–539 (2014).
   Google Scholar
• Nasr M, Ghorab MK, Abdelazem A. In vitro and in vivo evaluation of cubosomes containing 5-fluorouracil for liver targeting. Acta Pharm. Sin. B. 5(1), 79–88 (2015).
   PubMed Web of Science ®Google Scholar
• Teba HE, Khalil IA, El Sorogy HM. Novel cubosome based system for ocular delivery of acetazolamide. Drug Deliv. 28(1), 2177–2186 (2021).
   PubMed Web of Science ®Google Scholar
• Ahmed LM, Hassanein KM, Mohamed FA et al. Formulation and evaluation of simvastatin cubosomal nanoparticles for assessing its wound healing effect. Sci. Rep. 13(1), 17941 (2023).
   PubMed Web of Science ®Google Scholar
• Zhang X, Xiao Y, Huang Z et al. Smart phase transformation system based on lyotropic liquid crystalline@hard capsules for sustained release of hydrophilic and hydrophobic drugs. Drug Deliv. 27(1), 449–459 (2020).
   PubMed Web of Science ®Google Scholar
• Khorsandi L, Mansouri E, Rashno M et al. Myricetin loaded solid lipid nanoparticles upregulate MLKL and RIPK3 in human lung adenocarcinoma. Int. J. Pept. Res. Ther. 26, 899–910 (2020).
   Web of Science ®Google Scholar
• Choi IS, Kim BS, Cho KS et al. Amiodarone induces apoptosis in L-132 human lung epithelial cell line. Toxicol. Lett. 132(1), 47–55 (2002).
   PubMed Web of Science ®Google Scholar
• Mehdi SH, Zafaryab M, Nafees S et al. Chrysin sensitizes human lung cancer cells to tumour necrosis factor related apoptosis-inducing ligand (TRAIL) mediated apoptosis. Asian Pacific J. Cancer Biol. 4(2), 27–33 (2019).
   Google Scholar
• Ragini SP, White J, Kirby N et al. Novel bioactive cationic cubosomes enhance the cytotoxic effect of paclitaxel against a paclitaxel resistant prostate cancer cell-line. J. Colloid Interf. Sci. 649, 966–976 (2023).
   PubMed Web of Science ®Google Scholar
• Jagwani S, Jalalpure S, Dhamecha D et al. Pharmacokinetic and pharmacodynamic evaluation of resveratrol loaded cationic liposomes for targeting hepatocellular carcinoma. ACS Biomater. Sci. Eng. 6(9), 4969–4984 (2020).
   PubMed Web of Science ®Google Scholar
• Franken NA, Rodermond HM, Stap J et al. Clonogenic assay of cells in vitro. Nat. Protoc. 1(5), 2315–2319 (2006).
   PubMed Web of Science ®Google Scholar
• Chen Y, Wu Q, Song L et al. Polymeric micelles encapsulating fisetin improve the therapeutic effect in colon cancer. ACS Appl. Mater Interf. 7(1), 534–542 (2015).
   PubMed Web of Science ®Google Scholar
• Pramanik A, Xu Z, Shamsuddin SH et al. Affimer tagged cubosomes: targeting of carcinoembryonic antigen expressing colorectal cancer cells using in vitro and in vivo models. ACS Appl. Mater Interf. 14(9), 11078–11091 (2022).
   PubMed Web of Science ®Google Scholar
• Heneczkowski M, Kopacz M, Nowak D et al. Infrared spectrum analysis of some flavonoids. Acta Pol. Pharm. – Drug Res. 58(6), 415–420 (2001).
   PubMedGoogle Scholar